Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2020)

Outlook Therapeutics (OTLK) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $109.0 as the latest value for Q2 2020.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $109.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $109.0, a N/A change, with the full-year FY2019 number at $4069.0, down 96.14% from a year prior.
  • Gains from Sales and Divestitures was $109.0 for Q2 2020 at Outlook Therapeutics, roughly flat from $109.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $105361.0 in Q3 2018 to a low of $109.0 in Q4 2019.
  • A 3-year average of $21951.4 and a median of $109.0 in 2019 define the central range for Gains from Sales and Divestitures.
  • Biggest YoY gain for Gains from Sales and Divestitures was 96.14% in 2019; the steepest drop was 96.14% in 2019.
  • Outlook Therapeutics' Gains from Sales and Divestitures stood at $105361.0 in 2018, then crashed by 99.9% to $109.0 in 2019, then changed by 0.0% to $109.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Gains from Sales and Divestitures are $109.0 (Q2 2020), $109.0 (Q1 2020), and $109.0 (Q4 2019).